Dikarbamin

General characteristics. Structure:

Active agent: имидазолилэтанамид pentandiovy acid (vitagluta) of 100 mg

Excipients: lactose, potato starch, silicon dioxide colloid (aerosil), talc, magnesium stearate, stearic acid.

Pharmacological properties:

Leukopoiesis stimulator. Accelerates a differentiation and functional maturing of neutrophils.
Gematoprotektorny action a dicarbamine at myelosuppressive chemotherapy is caused by acceleration of maturing of predecessors of neutrocytes on a mode of formation of specific granules. Reduction of degree and frequency of a toxic neutropenia of the III-IV degree results.
The therapeutic effect a dicarbamine is shown at daily use within 21-28 days during the period between the planned chemotherapy courses.
Causes reduction of the frequency of emergence limiting leucio-and neutropenias. Allows to carry out treatment to the planned terms without decrease in doses of tsitostatik and risk of hematologic complications.

Pharmacokinetics. Absorption. In 10 min. after intake drug is defined in a blood plasma. Cmax is reached in 30 min. and during 2 h decreases.

Distribution. It is quickly and evenly distributed on internals.

Removal. The considerable share of the administered drug is removed with urine.

Indications to use:

— a gematoprotektion at the patients receiving chemotherapy cytotoxic means concerning malignant new growths.

Route of administration and doses:

Drug should be accepted inside daily in a single dose of 100 mg (1 tablets) in 5 days prior to the beginning of the first course of chemotherapy and further throughout the entire period of chemotherapy.

Features of use:

There are no data.

Side effects:

Allergic reactions: seldom - skin rash.

Interaction with other medicines:

Дикарбамин® strengthens antineoplastic action of tsitostatik.

Дикарбамин® influences specific activity of cyclophosphamide and its combinations with platinum drugs (Cisplatinum and karboplatiny): simultaneous use of Dikarbamin with cytostatics leads to increase in intensity and duration of antineoplastic effect. Besides, Dikarbamin® reduces toxic effect of cyclophosphamide and its combinations with platinum drugs (Cisplatinum and karboplatiny) at Dikarbamin's introduction for 5 days prior to therapy by antineoplastic drugs and continuation of its reception further as before of dosing; prevents development of a deep cytopenia and accelerates hemopoiesis recovery processes.

Contraindications:

— hypersensitivity to a dicarbamine or to drug components.

Use at pregnancy and feeding by a breast
Use of drug at pregnancy is contraindicated.
In need of use of drug in the period of a lactation it is necessary to resolve an issue of the termination of breastfeeding for the period of treatment.

Overdose:

The specific antidote to a dicarbamine is unknown.

Storage conditions:

List B. Drug should be stored in the unavailable to children, dry, protected from light place at a temperature not above 25 °C.

Issue conditions:

According to the recipe

Packaging:

Tablets of 100 mg: 21 pieces.